# Grand Pharma acquires Shenming Medical for RMB22.6M

China Grand Pharmaceutical and Healthcare Holdings (GP HK) acquired 100% of Jiangsu Shenming Medical Technology for RMB22.6 million, obtaining rights to a thermosensitive embolic agent for liver cancer treatment.

- Type: Acquisition
- Announced: 2021-05-26
- Where: China
- Value: $3.50M (22.6M CNY)
- Status: announced
- Products: thermosensitive embolic agent for liver cancer
- Sectors: [Medical Devices](https://endata.com/sectors/medical-devices.md)

## Companies

- [China Grand Pharmaceutical and Healthcare](https://endata.com/companies/28136.md) (acquirer)
- [Jiangsu Shenming Medical Technology](https://endata.com/companies/55399.md) (target)

## Sources

- [grandpharm.com](https://www.grandpharm.com/en/news/gp-hk-acquires-shenming-medical-technology-co-ltd-obtains-all-rights-of-an-innovative-thermosensitive-embolic-agent-for-the-treatment-of-liver-cancer-further-expands-the-tumor-intervention-treat/), 2021-05-26: "the Group will invest RMB22.6 million and obtain 100% equity interest of Shenming Medical"

---
Data from Endata (https://endata.com/). Announcements are summarized from public sources and may be incomplete; check the linked originals.